4.7 Article

Postoperative Complications after Ileocecal Resection in Crohn's Disease: A Prospective Study From the REMIND Group

期刊

AMERICAN JOURNAL OF GASTROENTEROLOGY
卷 112, 期 2, 页码 337-345

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1038/ajg.2016.541

关键词

-

资金

  1. Association Francois Aupetit
  2. MSD France
  3. Helmsley Charitable Trust

向作者/读者索取更多资源

OBJECTIVES: We sought to determine the frequency of and risk factors for early (30-day) postoperative complications after ileocecal resection in a well-characterized, prospective cohort of Crohn's disease patients. METHODS: The REMIND group performed a nationwide study in 9 French university medical centers. Clinical-, biological-, surgical-, and treatment-related data on the 3 months before surgery were collected prospectively. Patients operated on between 1 September 2010 and 30 August 2014 were included. RESULTS: A total of 209 patients were included. The indication for ileocecal resection was stricturing disease in 109 (52%) cases, penetrating complications in 88 (42%), and medication-refractory inflammatory disease in 12 (6%). A two-stage procedure was performed in 33 (16%) patients. There were no postoperative deaths. Forty-three (21%) patients (23% of the patients with a one-stage procedure vs. 9% of those with a two-stage procedure, P=0.28) experienced a total of 54 early postoperative complications after a median time interval of 5 days (interquartile range, 4-12): intra-abdominal septic complications (n=38), extraintestinal infections (n=10), and hemorrhage (n=6). Eighteen complications (33%) were severe (Dindo-Clavien III-IV). Reoperation was necessary in 14 (7%) patients, and secondary stomy was performed in 8 (4.5%). In a multivariate analysis, corticosteroid treatment in the 4 weeks before surgery was significantly associated with an elevated postoperative complication rate (odds ratio (95% confidence interval)=2.69 (1.15-6.29); P=0.022). Neither preoperative exposure to anti-tumor necrosis factor (TNF) agents (n=93, 44%) nor trough serum anti-TNF levels were significant risk factors for postoperative complications. CONCLUSIONS: In this large, nationwide, prospective cohort, postoperative complications were observed after 21% of the ileocecal resections. Corticosteroid treatment in the 4 weeks before surgery was significantly associated with an elevated postoperative complication rate. In contrast, preoperative anti-TNF therapy (regardless of the serum level or the time interval between last administration and surgery) was not associated with an elevated risk of postoperative complications.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Gastroenterology & Hepatology

I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

Laurent Peyrin-Biroulet, Jean-Francois Rahier, Julien Kirchgesner, Vered Abitbol, Sebastian Shaji, Alessandro Armuzzi, Konstantinos Karmiris, Javier P. Gisbert, Peter Bossuyt, Ulf Helwig, Johan Burisch, Henit Yanai, Glen A. Doherty, Fernando Magro, Tamas Molnar, Mark Lowenberg, Jonas Halfvarson, Edyta Zagorowicz, Helene Rousseau, Cedric Baumann, Filip Baert, Laurent Beaugerie

Summary: The I-CARE study aims to evaluate the benefit-risk ratio of current therapies in IBD patients. It collected data from 10,206 patients and observed the treatment risks of anti-tumor necrosis factor and other biologic therapies, particularly the risks of cancer/lymphoma and serious infections. The results showed that different treatment regimens had varying effects on patients, and further research is needed to assess specific risks.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

CARD9 in neutrophils protects from colitis and controls mitochondrial metabolism and cell survival

Camille Danne, Chloe Michaudel, Jurate Skerniskyte, Julien Planchais, Aurelie Magniez, Allison Agus, Marie-Laure Michel, Bruno Lamas, Gregory Da Costa, Madeleine Spatz, Cyriane Oeuvray, Chloe Galbert, Maxime Poirier, Yazhou Wang, Alexia Lapiere, Nathalie Rolhion, Tatiana Ledent, Cedric Pionneau, Solenne Chardonnet, Floriant Bellvert, Edern Cahoreau, Amandine Rocher, Rafael Rose Arguello, Carole Peyssonnaux, Sabine Louis, Mathias L. Richard, Philippe Langella, Jamel El-Benna, Benoit Marteyn, Harry Sokol

Summary: Inflammatory bowel disease (IBD) is caused by a combination of genetic predisposition, gut microbiota dysbiosis, and environmental factors. Caspase recruitment domain 9 (Card9) is an IBD susceptibility gene that has been shown to protect against intestinal inflammation and fungal infection. However, the specific cell types and mechanisms involved in the CARD9 protective role against inflammation are still unknown.
Article Gastroenterology & Hepatology

Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases

Chloe Michaudel, Camille Danne, Allison Agus, Aurelie Magniez, Anne Aucouturier, Madeleine Spatz, Antoine Lefevre, Julien Kirchgesner, Nathalie Rolhion, Yazhou Wang, Aonghus Lavelle, Chloe Galbert, Gregory Da Costa, Maxime Poirier, Alexia Lapiere, Julien Planchais, Petr Nadvornik, Peter Illes, Cyriane Oeuvray, Laura Creusot, Marie-Laure Michel, Nicolas Benech, Anne Bourrier, Isabelle Nion-Larmurier, Cecilia Landman, Mathias L. Richard, Patrick Emond, Philippe Seksik, Laurent Beaugerie, Rafael Rose Arguello, David Moulin, Sridhar Mani, Zdenek Dvorak, Luis G. Bermudez-Humaran, Philippe Langella, Harry Sokol

Summary: This study identified a new mechanism linking tryptophan metabolism to intestinal inflammation and inflammatory bowel diseases (IBDs). Bringing back xanthurenic acid (XANA) and kynurenic acid (KYNA) has protective effects involving Aryl hydrocarbon Receptor (AhR) activation and the rewiring of cellular energy metabolism in intestinal epithelial cells and CD4(+) T cells. Manipulating the endogenous metabolic pathway with aminoadipate aminotransferase (AADAT) may provide new therapeutic strategies for correcting tryptophan metabolism alterations in IBD.
Article Gastroenterology & Hepatology

Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent

Anthony Buisson, Maria Nachury, Thomas Guilmoteau, Romain Altwegg, Xavier Treton, Mathurin Fumery, Melanie Serrero, Eloise Leclerc, Ludovic Caillo, Bruno Pereira, Aurelien Amiot, Guillaume Bouguen

Summary: This multicenter study compared the effectiveness of tofacitinib and vedolizumab in patients with ulcerative colitis. The results showed that tofacitinib had better clinical remission and endoscopic improvement, especially in severe disease and primary failure to biologics.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Letter Gastroenterology & Hepatology

Can Subcutaneous Infliximab Replace Dose-Intensified Intravenous Administration in Inflammatory Bowel Disease? Reply

Anthony Buisson, Maria Nachury, Mathurin Fumery

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Letter Gastroenterology & Hepatology

Fecal Mucin O-Glycans as Novel Biomarkers in Inflammatory Bowel Diseases

Catherine Robbe Masselot, Camille Cordier, Benjamin Marsac, Maria Nachury, Renaud Leonard, Boualem Sendid

INFLAMMATORY BOWEL DISEASES (2023)

Article Multidisciplinary Sciences

Questioning the fetal microbiome illustrates pitfalls of low-biomass microbial studies

Katherine M. Kennedy, Marcus C. de Goffau, Maria Elisa Perez-Munoz, Marie-Claire Arrieta, Fredrik Backhed, Peer Bork, Thorsten Braun, Frederic D. Bushman, Joel Dore, Willem M. de Vos, Ashlee M. Earl, Jonathan A. Eisen, Michal A. Elovitz, Stephanie C. Ganal-Vonarburg, Michael G. Ganzle, Wendy S. Garrett, Lindsay J. Hall, Mathias W. Hornef, Curtis Huttenhower, Liza Konnikova, Sarah Lebeer, Andrew J. Macpherson, Ruth C. Massey, Alice Carolyn McHardy, Omry Koren, Trevor D. Lawley, Ruth E. Ley, Liam O'Mahony, Paul W. O'Toole, Eric G. Pamer, Julian Parkhill, Jeroen Raes, Thomas Rattei, Anne Salonen, Eran Segal, Nicola Segata, Fergus Shanahan, Deborah M. Sloboda, Gordon C. S. Smith, Harry Sokol, Tim D. Spector, Michael G. Surette, Gerald W. Tannock, Alan W. Walker, Moran Yassour, Jens Walter

Summary: The colonization of microbial communities in the human fetus and the prenatal intrauterine environment is still controversial. Recent studies analyzing microbial populations in human fetuses indicate that the detected signals might be due to contamination during sample collection or DNA sequencing processes. The presence of live and replicating microbial populations in healthy fetal tissues contradicts fundamental concepts in immunology and clinical microbiology. This has significant implications for our understanding of human immune development and highlights the challenges in studying microbial communities in low-biomass environments.

NATURE (2023)

Article Substance Abuse

Engineered bacteria producing aryl-hydrocarbon receptor agonists protect against ethanol-induced liver disease in mice

Tetsuya Kouno, Suling Zeng, Yanhan Wang, Yi Duan, Sonja Lang, Bei Gao, Phillipp Hartmann, Noemi Cabre, Cristina Llorente, Chloe Galbert, Patrick Emond, Harry Sokol, Michael James, Chun Cheih Chao, Jian-Rong Gao, Mylene Perreault, David L. Hava, Bernd Schnabl

Summary: This study demonstrates that engineering gut bacteria to produce tryptophan metabolites can alleviate liver disease caused by alcohol through Ahr activation in intestinal immune cells.

ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH (2023)

Article Genetics & Heredity

Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

Daniela Matuozzo, Estelle Talouarn, Astrid Marchal, Peng Zhang, Jeremy Manry, Yoann Seeleuthner, Yu Zhang, Alexandre Bolze, Matthieu Chaldebas, Baptiste Milisavljevic, Adrian Gervais, Paul Bastard, Takaki Asano, Lucy Bizien, Federica Barzaghi, Hassan Abolhassani, Ahmad Abou Tayoun, Alessandro Aiuti, Ilad Alavi Darazam, Luis M. Allende, Rebeca Alonso-Arias, Andres Augusto Arias, Gokhan Aytekin, Peter Bergman, Simone Bondesan, Yenan T. Bryceson, Ingrid G. Bustos, Oscar Cabrera-Marante, Sheila Carcel, Paola Carrera, Giorgio Casari, Khalil Chaibi, Roger Colobran, Antonio Condino-Neto, Laura E. Covill, Ottavia M. Delmonte, Loubna El Zein, Carlos Flores, Peter K. Gregersen, Marta Gut, Filomeen Haerynck, Rabih Halwani, Selda Hancerli, Lennart Hammarstroem, Nevin Hatipoglu, Adem Karbuz, Sevgi Keles, Christele Kyheng, Rafael Leon-Lopez, Jose Luis Franco, Davood Mansouri, Javier Martinez-Picado, Ozge Metin Akcan, Isabelle Migeotte, Pierre-Emmanuel Morange, Guillaume Morelle, Andrea Martin-Nalda, Giuseppe Novelli, Antonio Novelli, Tayfun Ozcelik, Figen Palabiyik, Qiang Pan-Hammarstroem, Rebeca Perez de Diego, Laura Planas-Serra, Daniel E. Pleguezuelo, Carolina Prando, Aurora Pujol, Luis Felipe Reyes, Jacques G. Riviere, Carlos Rodriguez-Gallego, Julian Rojas, Patrizia Rovere-Querini, Agatha Schlueter, Mohammad Shahrooei, Ali Sobh, Pere Soler-Palacin, Yacine Tandjaoui-Lambiotte, Imran Tipu, Cristina Tresoldi, Jesus Troya, Diederik van de Beek, Mayana Zatz, Pawel Zawadzki, Saleh Zaid Al-Muhsen, Mohammed Faraj Alosaimi, Fahad M. Alsohime, Hagit Baris-Feldman, Manish J. Butte, Stefan N. Constantinescu, Megan A. Cooper, Clifton L. Dalgard, Jacques Fellay, James R. Heath, Yu-Lung Lau, Richard P. Lifton, Tom Maniatis, Trine H. Mogensen, Horst von Bernuth, Alban Lermine, Michel Vidaud, Anne Boland, Jean-Francois Deleuze, Robert Nussbaum, Amanda Kahn-Kirby, France Mentre, Sarah Tubiana, Guy Gorochov, Florence Tubach, Pierre Hausfater, C. O. V. I. D. Human Genetic Effort, Isabelle Meyts, Shen-Ying Zhang, Anne Puel, Luigi D. Notarangelo, Stephanie Boisson-Dupuis, Helen C. Su, Bertrand Boisson, Emmanuelle Jouanguy, Jean-Laurent Casanova, Qian Zhang, Laurent Abel, Aurelie Cobat

Summary: Through a genome-wide rare variant burden association analysis, it was found that there is an association between at-risk variants in the TLR7 gene and rare loss-of-function variants in TLR3-dependent type I interferon immunity genes. These findings suggest that rare variants in TLR3- and TLR7-dependent type I interferon immunity genes may underlie life-threatening COVID-19 in patients under 60 years old.

GENOME MEDICINE (2023)

Article Geriatrics & Gerontology

Impairment of aryl hydrocarbon receptor signalling promotes hepatic disorders in cancer cachexia

Adeline Dolly, Sarah A. Potgens, Morgane M. Thibaut, Audrey M. Neyrinck, Gabriela S. de Castro, Chloe Galbert, Camille Lefevre, Elisabeth Wyart, Silvio P. Gomes, Daniela C. Goncalves, Nicolas Lanthier, Pamela Baldin, Joshua R. Huot, Andrea Bonetto, Marilia Seelaender, Nathalie M. Delzenne, Harry Sokol, Laure B. Bindels

Summary: This study explores the potential role of the aryl hydrocarbon receptor (AHR) in cancer cachexia and finds that impaired AHR signaling contributes to hepatic inflammatory and metabolic disorders, exacerbating cachectic features. These findings provide innovative therapeutic strategies for cancer cachexia.

JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2023)

Article Immunology

Staphylococcus epidermidis isolates from atopic or healthy skin have opposite effect on skin cells: potential implication of the AHR pathway modulation

Leslie Landemaine, Gregory Da Costa, Elsa Fissier, Carine Francis, Stanislas Morand, Jonathan Verbeke, Marie-Laure Michel, Romain Briandet, Harry Sokol, Audrey Gueniche, Dominique Bernard, Jean-Marc Chatel, Luc Aguilar, Philippe Langella, Cecile Clavaud, Mathias L. Richard

Summary: This study demonstrates that Staphylococcus epidermidis strains originating from healthy skin and atopic skin have different effects. Strains from atopic skin alter the structure of a 3D reconstructed skin model, while strains from healthy skin do not. The metabolites produced by strains from healthy skin can activate the aryl hydrocarbon receptor pathway, while strains from atopic skin cannot.

FRONTIERS IN IMMUNOLOGY (2023)

Article Microbiology

Antibiotic treatment using amoxicillin-clavulanic acid impairs gut mycobiota development through modification of the bacterial ecosystem

Madeleine Spatz, Gregory Da Costa, Rebecka Ventin-Holmberg, Julien Planchais, Chloe Michaudel, Yazhou Wang, Camille Danne, Alexia Lapiere, Marie-Laure Michel, Kaija-Leena Kolho, Philippe Langella, Harry Sokol, Mathias L. Richard

Summary: This study investigated the effects of antibiotic treatment on the fungal microbiota in the gut. It was found that amoxicillin-clavulanic acid treatment led to a decrease in the overall fungal population in mouse feces and a remodeling of the fungal community. Certain bacterial strains were shown to inhibit fungal growth. This study provides new insights into the interactions between fungi and bacteria in the gut and may offer new strategies for modulating gut microbiota equilibrium.

MICROBIOME (2023)

Article Medicine, General & Internal

Development of Antibodies to Ustekinumab Is Associated with Loss of Response in Patients with Inflammatory Bowel Disease

Xavier Roblin, Gerard Duru, Konstantinos Papamichael, Adam S. Cheifetz, Sandy Kwiatek, Anne-Emmanuelle Berger, Mathilde Barrau, Louis Waeckel, Stephane Nancey, Stephane Paul

Summary: Monitoring of anti-drug antibodies in patients on ustekinumab is not recommended due to low immunogenicity. This study aimed to investigate the relationship between anti-drug antibodies and loss of response to ustekinumab in patients with IBD. The results showed that ATU was an independent predictor of LOR to ustekinumab in IBD patients.

JOURNAL OF CLINICAL MEDICINE (2023)

Review Microbiology

Targeting the gut microbiota in inflammatory bowel diseases: where are we?

Nicolas Benech, Harry Sokol

CURRENT OPINION IN MICROBIOLOGY (2023)

Review Gastroenterology & Hepatology

Use of imaging modalities for decision-making in inflammatory bowel disease

Stephane Nancey, Mathurin Fumery, Mathias Faure, Gilles Boschetti, Claire Gay, Laurent Milot, Xavier Roblin

Summary: Cross-sectional magnetic resonance enterography (MRE) and intestinal ultrasonography (IUS) are valuable and noninvasive imaging modalities for the assessment, monitoring, and prediction of disease activity and outcomes in inflammatory bowel disease (IBD) patients. However, the underutilization of IUS in clinical practice is due to the lack of validated indices and trained gastroenterologists and radiologists. Nevertheless, the increasing evidence highlights the importance of both IUS and MRE in aiding clinical decision-making.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2023)

暂无数据